评估两种药物疗法对燃烧口腔综合征的疗效
1BDS, MDS, American Board of Orofacial Pain, Associate Professor, Department of Diagnostic Sciences and Oral Biology, College of Dentistry, King Khalid University, Abha, Saudi Arabia.
Journal of pharmacy & bioallied sciences
|September 30, 2024
概括
三环抗抑郁药 (TCA) 和抗药有效地治疗口腔炎综合征 (BMS),显著改善患者的疼痛,生活质量和心理困扰. 这两种治疗方法在最近的一项研究中都显示出可比的疗效.
科学领域:
- 口腔医学是指口腔医学.
- 药理学 药理学是指药理学的学科.
- 临床疼痛管理 临床疼痛管理
背景情况:
- 燃烧口腔综合征 (BMS) 是一种慢性口腔疼痛状况,严重影响患者的生活质量.
- 目前用于BMS的药理疗法缺乏对比疗效的数据,这在临床管理中造成了不确定性.
- 该研究解决了对常用的BMS药物剂进行基于证据的比较的需求.
研究的目的:
- 为了比较三环抗抑郁药 (TCA) 与抗药在管理BMS症状方面的疗效.
- 评估这些治疗对疼痛强度,口腔健康相关生活质量和心理痛苦的影响.
- 为优化BMS药理疗提供比较数据.
主要方法:
- 一项随机研究涉及80名被诊断患有BMS的参与者.
- 参与者被分配给接受TCA (A组) 或抗药 (B组).
- 包括疼痛强度 (VAS),生活质量和心理困扰在内的结果在基线,3个月和6个月被评估.
主要成果:
- 与基线相比,TCA和抗药都显著降低了疼痛强度,改善了生活质量,并减少了心理痛苦.
- 在6个月后,TCAs降低了70%的疼痛,而抗药降低了65%,两组之间没有统计学上显著的差异 (P=0.35).
- 两个治疗组在口腔健康相关的生活质量和心理困扰指标上均表现出相似的改善.
结论:
- 三环抗抑郁药 (TCA) 和抗药都是治疗口腔炎综合征的有效药物干预措施.
- 这些药物显著改善了疼痛,口腔健康相关的生活质量和心理困扰.
- 这项研究表明,TCA和抗药在BMS管理中具有可比的疗效.
相关概念视频
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
Drug Delivery: Enteral Route
386
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
386
Bioequivalence: Overview
935
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
935
Gastroesophageal Reflux Disease II: Clinical Features and Management
57
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
57
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
409
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
409


